Steroid Hormone Receptors and Human Breast Cancer
Steroid Hormone Receptors and Human Breast Cancer
复制标题
类固醇激素受体与人类乳腺癌
DOI：
--
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
V. Jordan
中科院分区：
文献类型：
--
作者：
Dawn M. Mirecki;V. Jordan
大约30%的乳腺癌患者对某种形式的内分泌治疗有反应。反应速率取决于肿瘤组织中雌激素受体（ER）和孕激素受体（PgR）的水平。虽然约60%的ER阳性晚期乳腺肿瘤对内分泌治疗有客观反应，但高达80%的ER阳性和PgR阳性肿瘤都会有反应。肿瘤标本中受体的定量评估也导致使用ER和PgR作为乳腺切除术后无疾病间隔的预后指标。一般来说，类固醇激素受体阳性的原发性肿瘤患者在复发前的无病期比激素受体阴性的肿瘤患者长。受体水平与年龄有关：与老年妇女相比，年轻妇女的ER水平较低。ER的单克隆抗体测定的最新发展可能允许更精确的预测患者对激素操作的反应。
Approximately 30% of all breast cancer patients will respond to some form of endocrine therapy. The rate of response depends on the level of estrogen receptors (ER) and progesterone receptors (PgR) in the tumor tissue. While approximately 60% of ER-positive advanced breast tumors will respond objectively to endocrine therapy, up to 80% of both ER-positive and PgR-positive tumors will respond. The quantitative assessment of receptors in tumor specimens has also led to the use of ER and PgR as prognostic indicators of disease-free intervals following mastectomy. In general, patients with steroid hormone receptor-positive primary tumors have longer disease-free intervals before recurrence than those with hormone receptor-negative tumors. Receptor levels are related to age: lower levels of ER are observed in younger women compared with older women. The recent development of monoclonal antibody assays for ER may allow for more precise predictions of the response of patients to hormonal manipulation.